RAP 0.00% 20.5¢ resapp health limited

2020 commercialisation, page-533

  1. 172 Posts.
    lightbulb Created with Sketch. 82
    Is $300k in customer receipts with costs staying the same as last quarter a big ask?

    If we can achieve that then at least there wouldn't be any change to how many quarters we'd have before we run out of cash. Q2 would need to be about $450k and Q3 would need to be about $570k. This would continue to buy us time to materialise the "alternative/plentiful revenue streams" that we expect to come good in the future.

    To this end, I don't think that my forecasted customer receipts are too optimistic or unachievable, but the big unknown is whether anyone has paid us anything during the last quarter. I'm hopeful that they have kept costs under control. All will be revealed in the upcoming 4c.

    This is all just pure speculation and my own opinion. not to be take as advice. do your own research. gltah.
    Last edited by NoEggspurt: 23/10/20
 
watchlist Created with Sketch. Add RAP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.